By playing, you agree to uListen's Terms and Privacy Policy and YouTube's Terms of Service.
Peter Attia MD#42–Avrum Bluming, M.D. and Carol Tavris, Ph.D.: A compelling case for hormone replacement therapy
Summaries, chapters, transcripts, and FAQs on this page are made by uListen, not YouTube.
At a glance
WHAT IT’S REALLY ABOUT
Bluming and Tavris Challenge the Women's Health Initiative's Case Against Hormone Therapy
- Bluming and Tavris recount how breast cancer treatment long rested on the assumption that estrogen causes the disease, leading to aggressive procedures on women that were never tried on men.
- They critique the 2002 Women's Health Initiative, citing an older, unhealthy study population, exclusion of highly symptomatic women, a press release ahead of the journal article, and a breast cancer signal that was not statistically significant.
- They walk through the evidence for benefits of estrogen on Alzheimer's risk, heart disease, hip fracture and colon cancer, alongside real risks such as blood clots and gallstones.
- The discussion widens to evidence quality, arguing that randomized trials and observational studies each have flaws and that convergent evidence from many directions matters most.
- Both authors stress the book's aim is to empower women to weigh the data with their physicians, while acknowledging open questions such as HRT after breast cancer.
IDEAS WORTH REMEMBERING
5 ideasEstrogen drops sharply at menopause and symptoms last longer than assumed
Bluming says estrogen falls to about 1% of premenopausal levels, and symptoms last around seven and a half years on average, not one or two, often with depression, joint pain and cognitive problems misattributed to other causes.
The WHI population was not representative of women starting menopause
Tavris says the average age was 63, most women were overweight or obese, more than half were smokers, and highly symptomatic women were excluded, yet the results were extended to all women.
The reported breast cancer increase was small and contested
The 26% relative increase with estrogen plus progestin was not statistically significant, amounted to under one extra case per thousand, and Bluming argues it arose from a control group with lower-than-expected risk because of prior hormone use.
Heart disease dwarfs breast cancer as a risk to women
Using a chart of ten-year mortality ratios, Attia shows heart disease is more likely to kill women than breast cancer at every age, about sevenfold across a lifetime.
Timing and preexisting disease matter for cardiovascular risk
Bluming says women with existing narrowed vessels or starting more than ten years after menopause face a raised risk mostly in the first year, whereas those starting near menopause without cardiovascular disease do not.
WORDS WORTH SAVING
5 quotesI'm a medical oncologist, and I don't yet know what cancer is. And I'm in very good company because I don't know anybody who knows what cancer is, even though many will tell you they do, and they're wrong.
— Dr. Avrum Bluming
Heart disease kills more women than the next sixteen causes of death, including all forms of cancer, AIDS, and accidents.
— Dr. Avrum Bluming
estrogen plummets to 1% of what it was before menopause. I think most women have no idea that it's that great a drop in estrogen levels
— Dr. Avrum Bluming
But the alternative to over-medicalizing our problems is not to under-medicalize them either.
— Dr. Carol Tavris
They have no incentive to. They are the Goliath. Why does Goliath want to argue with David and Jane?
— Dr. Carol Tavris
High quality AI-generated summary created from speaker-labeled transcript.
